Skip to main content

Table 1 Correlation between CENPF expression and clinicopathological characteristics

From: CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle

Characteristic

CENPF expression level

p-value

Low (n = 39)

High (n = 40)

Age, n (%)

0.571

 ≤ 50

22 (27.8%)

19 (24.1%)

 

 > 50

17 (21.5%)

21 (26.6%)

 

Gender, n (%)

0.196

 Female

27 (34.2%)

21 (26.6%)

 

 Male

12 (15.2%)

19 (24.1%)

 

Pathologic stage, n (%)

 < 0.001

 Stage I

8 (10.4%)

1 (1.3%)

 

 Stage II

25 (32.5%)

12 (15.6%)

 

 Stage III

4 (5.2%)

12 (15.6%)

 

 Stage IV

2 (2.6%)

13 (16.9%)

 

Tumor status, n (%)

 < 0.001

 Tumor free

28 (36.4%)

11 (14.3%)

 

 With tumor

11 (14.3%)

27 (35.1%)

 

New events, n (%)

 < 0.001

 No

28 (36.8%)

11 (14.5%)

 

 Yes

11 (14.5%)

26 (34.2%)

 

Residual tumora, n (%)

 < 0.001

 R0

38 (54.3%)

17 (24.3%)

 

 R1

0 (0%)

6 (8.6%)

 

 R2

0 (0%)

9 (12.9%)

 

Laterality, n (%)

0.436

 Left

20 (25.3%)

25 (31.6%)

 

 Right

19 (24.1%)

15 (19%)

 

Mitotane therapy, n (%)

0.259

 No

16 (21.3%)

10 (13.3%)

 

 Yes

22 (29.3%)

27 (36%)

 

Weiss score, n (%)

0.002

 2

3 (4.9%)

0 (0%)

 

 3

9 (14.8%)

2 (3.3%)

 

 4

7 (11.5%)

2 (3.3%)

 

 5

5 (8.2%)

2 (3.3%)

 

 6

3 (4.9%)

5 (8.2%)

 

 7

5 (8.2%)

4 (6.6%)

 

 8

1 (1.6%)

8 (13.1%)

 

 9

0 (0%)

5 (8.2%)

 
  1. aResidual tumor: R0, no residual tumor; R1, residual tumor under the microscope; R2, residual tumor under-eye field